Blood-based biomarker tests can now detect Alzheimer's with roughly 90% accuracy through a simple blood draw — so why aren't they everywhere? The Milken Institute set out to answer that question, and their new report, Advancing Blood-Based Biomarkers for Alzheimer's and Cognitive Care, is the most rigorous look yet at what's standing in the way.

Drawing on interviews with 32 experts, a review of current literature, and a patient focus group, the report documents four real-world examples of health systems that have already made these tests a routine part of cognitive care — and makes a clear case that what worked there can work everywhere, if the right policy and coverage decisions follow.

The barriers are real, but so are the solutions. The report closes with concrete recommendations for stakeholders across the healthcare system, using coverage changes for genetic testing as a proven roadmap. For anyone serious about making early Alzheimer's detection the standard of care, this is required reading. Access the full report here: Advancing Blood-Based Biomarkers for Alzheimer's and Cognitive Care

‍